ReviewFrontiers in nutrition2026
Digital health technologies for the management of sarcopenia in patients receiving maintenance hemodialysis: a narrative review.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digital health technologies are increasingly being explored as supportive tools for managing sarcopenia in patients undergoing maintenance hemodialysis (MHD). Wearable devices, mobile health applications, telemedicine platforms, artificial intelligence, and virtual or augmented reality may support monitoring, patient engagement, and intervention delivery. However, the evidence remains heterogeneous, and the clinical readiness of different digital modalities varies substantially. Activity monitors, mobile applications, and remote follow-up platforms are relatively feasible for clinical or home-based supportive management, whereas continuous biosensors and some AI-driven prediction systems remain largely at the proof-of-concept or early validation stage. This narrative review synthesizes current applications, potential effects, limitations, and future directions of digital health technologies in the management of sarcopenia among MHD patients. Particular attention is given to internationally representative evidence because many existing studies are concentrated in specific regional or healthcare contexts. The review also discusses how digital tools may support MHD-specific monitoring by integrating data on interdialytic weight gain, volume fluctuations, dialysis adequacy, dialysis- and non-dialysis-day activity patterns, and laboratory indicators related to nutrition, inflammation, and uremic toxin burden. Further multicenter studies, quantitative comparisons across modalities, and rigorous clinical validation are needed before these technologies can be widely implemented.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.